XOMA Royalty Corp.

NASDAQ:XOMA

Biotechnology

Healthcare
$40.17 +0.44%

+$0.19 today

Market cap
$503.77M
Beta
0.87
P/E (TTM)
15.8
EPS (TTM)
$2.65
52W Low $22.29High $42.81

Volume 4.22M

Average 0.21M

XOMA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

XOMA Royalty Corp.NASDAQ: XOMA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 17.42M shares rose 18.2% year over year, behind the +43.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +18.2% toward the trailing-twelve-month pace of +43.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
17.42M-3.7% QoQ
Last fiscal yearDec 2025
17.98M+53.7% YoY
LTMMar 2026
17.85M+43.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.2%——
1 year+53.7%——
3-year CAGR+16.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
17.98M USD
Year-over-year change
+53.7%
4-year CAGR
+10.2%

Weighted Avg Shares (Diluted) vs competitors

How XOMA compares with its peers on the latest reported figures

  • XOMA's LTM Mar 2026 weighted avg shares (diluted) of 17.85M shares is the lowest of the 10 companies compared; the peer median is 64.33M shares.
  • Its year-over-year change of +43.0% is the 3rd highest of 10, against a peer median of +16.1%.
  • Over three fiscal years its annual growth of +16.4% compares with a peer median of +21.1%.
XOMA Competitors Peer median
Weighted Avg Shares (Diluted) for XOMA and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
QSIQuantum-Si incorporatedLTM Mar 2026201.73M +31.6%+12.4%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
GALTGalectin Therapeutics Inc.LTM Mar 202664.33M +2.7%+2.5%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
XOMAXOMA Royalty Corp.LTM Mar 202617.85M +43.0%+16.4%
Peer median (excluding XOMA) 64.33M+16.1%+21.1%

Competitors are the stored peer set for XOMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.16M6.03M4.76M28.49M52.15M
Cost of Revenue171K274K143K206K2.96M
Gross Profit37.99M5.75M4.62M28.28M49.18M
Gross Margin99.6%95.5%97.0%99.3%94.3%
Research & Development171K153K143K2.88M1.71M
Selling, General & Admin20.46M23.19M27.18M34.48M36.09M
Operating Expenses20.46M23.17M46.46M68.26M37.79M
Depreciation & Amortization167K274K900K216K2.97M
EBITDA16.52M(16.85M)(22.56M)(5.42M)47.82M
EBITDA Margin43.3%-279.5%-474.2%-19.0%91.7%
Operating Income17.53M(17.41M)(41.85M)(39.98M)11.38M
Operating Margin45.9%-288.9%-879.5%-140.3%21.8%
Interest Income0694K000
Interest Expense461K0569K13.84M13.03M
Other Income / Expenses(1.64M)295K1.02M20.5M20.43M
Income Before Tax15.89M(17.12M)(40.83M)(19.48M)31.82M
Pre-Tax Margin41.6%-284.0%-858.2%-68.4%61.0%
Income Tax Expense91K(15K)0(5.66M)103K
Net Income15.8M(17.1M)(40.83M)(13.82M)31.71M
Net Margin41.4%-283.8%-858.2%-48.5%60.8%
EPS (Basic)0.69(1.98)(4.04)(1.65)1.53
EPS (Diluted)0.65(1.98)(4.04)(1.65)1.46
Weighted Avg Shares11.29M11.41M11.47M11.7M17.98M
Weighted Avg Shares (Diluted)12.19M11.41M11.47M11.7M17.98M

XOMA Royalty Corp.

NASDAQ:XOMA

Intrinsic Alpha fair value

Locked

Current Price

$40.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.